CHG-2023-0122
Facility Change for Verasenib. Formulation Change for Verasenib — critical change. Impacts 4 markets and 3 variations.
Change Number
CHG-2023-0122
Type
Facility Change
Product
Status
Submitted
Owner
Nadia Petrova
Initiated
2022-07-15
Description
Formulation Change for Verasenib — critical change
Impacted Markets (4)
EU — European UnionFR — FranceTW — TaiwanSE — Sweden
Impacted Modules
3.2.S4.2.13.2.P
Linked Variations (0)
| Variation # | Type | Application | Status | Submitted | Approved |
|---|